Electronic tool for argumentation and evidence sharing: For a global pharmaceutical company, CRA developed an electronic toolkit that presented evidence and arguments on a range of policy challenges and incorporated evidence of the company’s economic footprint.
Regional policy development: Consistency of arguments across countries and regions is becoming increasingly important. A global pharmaceutical company asked CRA to work with local affiliates to develop regional policy positions that were sustainable over the medium term.
Thematic evidence base development: Different countries often face similar challenges. Following the financial crisis, a global pharmaceutical company asked CRA to analyse the health care market across multiple countries and create a toolkit that demonstrated and quantified thematic evidence of potential inefficiencies.
How COVID-19 could revolutionize the UK pharmaceutical procurement landscape: A DOAC procurement case study
Direct oral anticoagulants (DOACs) are widely used pharmaceutical products which represent a significant cost to the healthcare system. In 2021, National...